Prognostic alternative splicing signatures in esophageal carcinoma

dc.contributor.authorDlamini, Zodwa
dc.contributor.authorHull, Rodney
dc.contributor.authorMbatha, Sikhumbuzo Z.
dc.contributor.authorAlaouna, Mohammed
dc.contributor.authorQiao, You-Lin
dc.contributor.authorYu, Herbert
dc.contributor.authorChatziioannou, Aristotelis
dc.contributor.emailzodwa.dlamini@up.ac.zaen_ZA
dc.date.accessioned2021-09-10T13:17:28Z
dc.date.available2021-09-10T13:17:28Z
dc.date.issued2021
dc.description.abstractAlternative splicing (AS) is a method of increasing the number of proteins that the genome is capable of coding for, by altering the pre-mRNA during its maturation. This process provides the ability of a broad range of proteins to arise from a single gene. AS events are known to occur in up to 94% of human genes. Cumulative data have shown that aberrant AS functionality is a major factor in human diseases. This review focuses on the contribution made by aberrant AS functionality in the development and progression of esophageal cancer. The changes in the pattern of expression of alternately spliced isoforms in esophageal cancer can be used as diagnostic or prognostic biomarkers. Additionally, these can be used as targets for the development of new treatments for esophageal cancer.en_ZA
dc.description.departmentSurgeryen_ZA
dc.description.librarianpm2021en_ZA
dc.description.urihttp://www.dovepress.com/cancer-management-and-research-journalen_ZA
dc.identifier.citationDlamini, Z., Hull, R., Mbatha, S.Z., Alaouna, M., Qiao, Y.L., Yu, H., Chatziioannou, A. Prognostic Alternative Splicing Signatures in Esophageal Carcinoma. Cancer Management and Research 2021;13:4509-4527. https://doi.org/10.2147/CMAR.S305464.en_ZA
dc.identifier.issn1179-1322 (print)
dc.identifier.other10.2147/CMAR.S305464
dc.identifier.urihttp://hdl.handle.net/2263/81754
dc.language.isoenen_ZA
dc.publisherDove Medical Pressen_ZA
dc.rights© 2021 Dlamini et al. This work is published and licensed by Dove Medical Press Limited and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.en_ZA
dc.subjectEsophageal squamous cell carcinomaen_ZA
dc.subjectAdenocarcinomaen_ZA
dc.subjectSplice variantsen_ZA
dc.subjectCell surface receptorsen_ZA
dc.subjectTherapeutic targetsen_ZA
dc.subjectBiomarkersen_ZA
dc.subjectAlternative splicingen_ZA
dc.titlePrognostic alternative splicing signatures in esophageal carcinomaen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Dlamini_Prognostic_2021.pdf
Size:
5.9 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: